Atlas Trials

SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

Clinical trial NCT07132242 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07132242
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer With HER2 Positive
Start date
2025-08-30
Primary completion
2028-08-30
Enrollment
84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.